Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Agrati C, Gioia C, Castilletti C, Lapa D, Berno G, Puro V, Carletti F, Cimini E, Nisii C, Castellino F, Martini F, Capobianchi MR.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1606-16. doi: 10.1089/AID.2011.0371. Epub 2012 May 8.

2.

Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.

Agrati C, Castilletti C, Cimini E, Lapa D, Quartu S, Caglioti C, Lanini S, Cattoli G, Martini F, Ippolito G, Capobianchi MR.

PLoS One. 2014 Aug 27;9(8):e105651. doi: 10.1371/journal.pone.0105651. eCollection 2014.

3.

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.

Herrera MT, Gonzalez Y, Juárez E, Hernández-Sánchez F, Carranza C, Sarabia C, Guzman-Beltran S, Manjarrez ME, Muñoz-Torrico M, Garcia-Garcia L, Sada E, Torres M.

BMC Infect Dis. 2013 Nov 15;13:544. doi: 10.1186/1471-2334-13-544.

4.

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.

Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.

Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3.

PMID:
21974995
5.

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.

Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ.

Hum Vaccin Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939.

6.

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.

Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, Echeverry M, Arango AE, Prada MC, Alarcon Hdel P, Rojas M.

Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8.

7.

Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.

Kelly D, Burt K, Missaghi B, Barrett L, Keynan Y, Fowke K, Grant M.

BMC Immunol. 2012 Aug 31;13:49. doi: 10.1186/1471-2172-13-49.

8.

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.

Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, Pinzani R, Zanetti A, Principi N.

J Med Virol. 2006 Apr;78(4):440-5.

PMID:
16482542
9.

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.

Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT.

Int J Infect Dis. 2012 Aug;16(8):e621-7. doi: 10.1016/j.ijid.2012.04.010. Epub 2012 Jun 15.

10.

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.

Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, van Dissel JT.

AIDS. 1998 Dec 3;12(17):F217-23.

PMID:
9863863
11.

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.

PLoS One. 2011 Jan 31;6(1):e16496. doi: 10.1371/journal.pone.0016496.

12.

CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.

Schmidt T, Dirks J, Enders M, Gärtner BC, Uhlmann-Schiffler H, Sester U, Sester M.

Eur J Immunol. 2012 Jul;42(7):1755-66. doi: 10.1002/eji.201242393.

13.

Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.

Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F.

Vaccine. 2012 Feb 21;30(9):1617-23. doi: 10.1016/j.vaccine.2011.12.107. Epub 2012 Jan 13.

PMID:
22245606
14.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
15.

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.

Ott U, Sauerbrei A, Lange J, Schäfler A, Walther M, Wolf G, Wutzler P, Zell R, Krumbholz A.

Med Microbiol Immunol. 2012 Aug;201(3):297-302. doi: 10.1007/s00430-012-0231-8. Epub 2012 Feb 17.

PMID:
22350187
16.

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, Tobudic S, Ramharter M, Wenisch J, Gualdoni GA, Redlberger-Fritz M, Popow-Kraupp T, Rieger A, Burgmann H.

PLoS One. 2012;7(5):e36773. doi: 10.1371/journal.pone.0036773. Epub 2012 May 21.

17.

Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.

Qiu C, Huang Y, Wang Q, Tian D, Zhang W, Hu Y, Yuan Z, Zhang X, Xu J.

Clin Infect Dis. 2012 Jan 1;54(1):17-24. doi: 10.1093/cid/cir753. Epub 2011 Nov 3.

18.

Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.

Strengell M, Ikonen N, Ziegler T, Kantele A, Anttila VJ, Julkunen I.

Influenza Other Respir Viruses. 2013 May;7(3):431-8. doi: 10.1111/j.1750-2659.2012.00415.x. Epub 2012 Aug 23.

19.

Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy.

Viganò A, Zuccotti GV, Pacei M, Erba P, Castelletti E, Giacomet V, Amendola A, Pariani E, Tanzi E, Clerici M.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):289-96. doi: 10.1097/QAI.0b013e3181632cda.

PMID:
18545155
20.

Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.

Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.

HIV Med. 2012 Jul;13(6):352-7. doi: 10.1111/j.1468-1293.2011.00987.x. Epub 2012 Feb 2.

Supplemental Content

Support Center